Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Overview
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Companies Involved in Therapeutics Development
180 Life Sciences Corp
Chimerix Inc
KaliVir Immunotherapeutics Inc
Shionogi & Co Ltd
TheraSource LLC
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Drug Profiles
dociparstat sodium – Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Inhibit HMGB1 for Parkinson’s Disease – Drug Profile
Product Description
Mechanism Of Action
HMGB1 – Drug Profile
Product Description
Mechanism Of Action
History of Events
JH-4 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclol Antibody to Inhibit HMGB1 for Influenza A Infections and Nervous System Disorders – Drug Profile
Product Description
Mechanism Of Action
Recombint High Mobility Group Protein B1 Replacement for Oncology – Drug Profile
Product Description
Mechanism Of Action
redasemtide trifluoroacetate – Drug Profile
Product Description
Mechanism Of Action
History of Events
TSA-521 – Drug Profile
Product Description
Mechanism Of Action
History of Events
VET-4H1 – Drug Profile
Product Description
Mechanism Of Action
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Dormant Products
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Product Development Milestones
Featured News & Press Releases
Dec 13, 2021: SHIONOGI announces positive results from a Phase 2 clinical trial of the regeneration inducing medicine S-005151 (Redasemtide) in patients with acute ischemic stroke
Feb 25, 2021: Chimerix reports promising topline results from first cohort of a randomized COVID-19 trial with DSTAT
Feb 25, 2021: Chimerix reports promising topline results from first cohort of a randomized COVID-19 trial with DSTAT
Apr 29, 2020: Chimerix announces initiation of a phase 2/3 study of DSTAT in acute lung injury for patients with severe COVID-19
Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting
Jun 04, 2018: Cantex Pharmaceuticals Announces That Clinical Trial Data For CX-01 In Refractory Acute Myeloid Leukemia And Myelodysplastic Syndrome Will Be Presented At The 2018 ASCO Annual Meeting
Mar 12, 2018: Publication in Blood Advances Reports that the Combition of Cantex Pharmaceuticals CX-01 with Chemotherapy for the Treatment of Acute Myeloid Leukemia Showed Encouraging Complete Remission Rates and Rapid Platelet Count Recovery
Jan 03, 2018: Cantex Pharmaceuticals Announces FDA Orphan Drug Desigtion Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia
Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01
May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting
Feb 09, 2005: ParinGenix Gets FDA Approval of IND for PGX-100
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 180 Life Sciences Corp, 2022
Pipeline by Chimerix Inc, 2022
Pipeline by KaliVir Immunotherapeutics Inc, 2022
Pipeline by Shionogi & Co Ltd, 2022
Pipeline by TheraSource LLC, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)